Drugs / Polydeoxyribonucleotides
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04401735 | Nov 2019 → May 2020 | lumbar spinal stenosis | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06309719 | Oct 2024 → Dec 2026 expected | periodontitis | Queen Mary University of London | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polydeoxyribonucleotides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06309719 ↗ |
| Known as | PDRN | “Polydeoxyribonucleotide(PDRN) 5.625mg/3ml” NCT04401735 ↗ |
| Modality | Oligonucleotide (other) | “Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)” NCT06309719 ↗ |